SCHEMBL12671818

SCHEMBL12671818

Bc1cc(/C=N/NC(=O)CNc2ccc3ccccc3c2)cc(Br)c1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.70
MEN1 O00255 9/20 0.66
KMT2A Q03164 9/20 0.66
MAPT P10636 10/20 0.61
KDM4E B2RXH2 3/20 0.61
ALDH1A1 P00352 3/20 0.61
GAA P10253 1/20 0.56
TDP1 Q9NUW8 2/20 0.54
LMNA P02545 1/20 0.52
MITF O75030 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
GRK2 P25098 4/20 0.49
ERCC1 P07992 2/20 0.48
ERCC4 Q92889 2/20 0.48
POLB P06746 2/20 0.47
MAPK1 P28482 1/20 0.47
ROCK2 O75116 1/20 0.47
CHEK1 O14757 1/20 0.47
AURKA O14965 1/20 0.47
DAPK3 O43293 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12648528 0.93 CFTR (0.77) CFTRMEN1KMT2AMAPTKDM4E
SCHEMBL12648544 0.89 CFTR (0.72) CFTRMEN1KMT2AMAPTKDM4E
SCHEMBL14082217 0.85 MEN1 (0.67) CFTRMEN1KMT2AMAPTKDM4E
SCHEMBL12671819 0.83 CHEK1 (0.51) CFTRMEN1KMT2AMAPTKDM4E
SCHEMBL17133546 0.83 CFTR (0.86) CFTRMEN1KMT2AMAPTKDM4E
SCHEMBL12648530 0.82 CFTR (1.00) CFTRMEN1KMT2AMAPTKDM4E
SCHEMBL29587254 0.82 CFTR (1.00) CFTRMEN1KMT2AMAPTKDM4E
SCHEMBL14082240 0.82 MEN1 (0.63) CFTRMEN1KMT2AMAPTKDM4E
SCHEMBL29380980 0.82 CFTR (1.00) CFTRMEN1KMT2AMAPTKDM4E
SCHEMBL12648541 0.82 MAPT (0.77) CFTRMEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105565-A1 WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-05-05 US disclosed
US-7888332-B2 Hydrazide-containing CFTR inhibitor compounds and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-02-15 US disclosed
US-20090048207-A1 HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048207-A1 HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF CFTR, ABCC5, SLC9A5 CFTR 1/4885MEN1 3964/4885KMT2A 3064/4885
US-20110105565-A1 WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, PKD1, PKD2 CFTR 1/4885MEN1 2136/4885KMT2A 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.